Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Itezocabtagene autoleucel by Tessa Therapeutics for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
Itezocabtagene autoleucel is under clinical development by Tessa Therapeutics and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According...
Itezocabtagene autoleucel by Tessa Therapeutics for Natural Killer Cell Lymphomas: Likelihood of Approval
Itezocabtagene autoleucel is under clinical development by Tessa Therapeutics and currently in Phase I for Natural Killer Cell Lymphomas. According...
Itezocabtagene autoleucel by Tessa Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Itezocabtagene autoleucel is under clinical development by Tessa Therapeutics and currently in Phase I for Diffuse Large B-Cell Lymphoma. According...
Itezocabtagene autoleucel by Tessa Therapeutics for Non-Hodgkin Lymphoma: Likelihood of Approval
Itezocabtagene autoleucel is under clinical development by Tessa Therapeutics and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData,...